deferasirox

FDA Drug Profile — Exjade, Deferasirox, Jadenu, Deferasirox Oral Granules, deferasirox

deferasirox is listed in the FDA National Drug Code directory with 31 NDC codes, marketed under brand names including Exjade, Deferasirox, Jadenu. Available dosage forms: tablet, for suspension, granule, tablet, film coated, powder.

Drug details

Generic Name
deferasirox
Brand Names
Exjade, Deferasirox, Jadenu, Deferasirox Oral Granules, deferasirox
Application Number
NDA021882
Sponsor
Novartis Pharmaceuticals Corporation
NDC Codes
31
Dosage Forms
TABLET, FOR SUSPENSION, GRANULE, TABLET, FILM COATED, POWDER
Routes
ORAL
Active Ingredients
DEFERASIROX

Indications and Usage

1 INDICATIONS AND USAGE Exjade is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Exjade is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L. ( 1.2 ) Limitations of Use: The safety and efficacy of Exjade when administered with other iron chelation therapy have not been established. ( 1.3 ) 1.1 Treatment of Chronic Iron Overload Due to Blood Transfusions (Transfusional Iron Overload) Exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older. 1.2 Treatment of Chronic Iron Overload in Non-Transfusion-Dependent Thalassemia Syndromes Exjade is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and a serum ferritin greater than 300 mcg/L. 1.3 Limitations of Use The safety and efficacy of Exjade when administered with other iron chelation therapy have not been established.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.